Lv1
10 积分 2021-11-08 加入
Early initiation of low-dose gilteritinib maintenance improves posttransplant outcomes in patients with R/R FLT3mut AML
3天前
已完结
Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML
3天前
已完结
The role of FLT3 in haematopoietic malignancies
2个月前
已完结
Mutation spectrum of FLT3 and significance of non‐canonical FLT3 mutations in haematological malignancy
2个月前
已完结
Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML
2个月前
已完结
Very poor long-term survival in past and more recent studies for relapsed AML patients: The ECOG-ACRIN experience
2个月前
已完结
儿童急性髓系白血病诊疗专家共识（2024）
2个月前
已完结
Phase 3 study of gilteritinib versus salvage chemotherapy in predominantly Asian patients with relapsed/refractory FLT3-mutated acute myeloid leukemia
3个月前
已完结
Follow-up of patients with R/R FLT3-mutation–positive AML treated with gilteritinib in the phase 3 ADMIRAL trial
4个月前
已关闭
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party
4个月前
已完结
皖公网安备34019202002308
